58 studies found for:    Open Studies | "Breast Neoplasms, Male"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Breast Neoplasms, Male" (58 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention:
2 Unknown  A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Veliparib;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
4 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis
5 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Glioblastoma;   Adult Soft Tissue Sarcoma;   Adult Solid Neoplasm;   Anaplastic Oligoastrocytoma;   Endometrial Serous Adenocarcinoma;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   Hormone-Resistant Prostate Cancer;   Male Breast Carcinoma;   Metastatic Prostate Carcinoma;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Resectable Hepatocellular Carcinoma;   Stage IA Breast Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Corpus Cancer;   Stage IA Uterine Sarcoma;   Stage IB Breast Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Corpus Cancer;   Stage IB Uterine Sarcoma;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Uterine Corpus Cancer;   Stage IIA Breast Cancer;   Stage IIA Lung Carcinoma;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Breast Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Lung Carcinoma;   Stage IIB Ovarian Cancer;   Stage IIB Skin Melanoma;   Stage IIB Uterine Sarcoma;   Stage IIC Ovarian Cancer;   Stage IIC Skin Melanoma;   Stage IIIA Breast Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Ovarian Cancer;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Breast Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Uterine Corpus Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Corpus Cancer;   Stage IVB Uterine Sarcoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
6 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Conditions: Male Breast Carcinoma;   Prostate Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Prostate Cancer
Intervention: Radiation: Stereotactic Radiosurgery
7 Recruiting FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Fluorothymidine F-18;   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis
8 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Carcinoma;   Extra-Adrenal Paraganglioma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Gastrin-Producing Neuroendocrine Tumor;   Hepatic Complication;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lung Carcinoid Tumor;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Male Breast Carcinoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Nasal Cavity Inverted Papilloma;   Nodal Marginal Zone Lymphoma;   Olfactory Neuroblastoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Inverted Schneiderian Papilloma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Lip Basal Cell Carcinoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Merkel Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasal Type NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Olfactory Neuroblastoma;   Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Oral Cavity Mucoepidermoid Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Oropharyngeal Undifferentiated Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Adrenal Gland Pheochromocytoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Small Intestinal Lymphoma;   Somatostatin-Producing Neuroendocrine Tumor;   Splenic Marginal Zone Lymphoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage III Adult Soft Tissue Sarcoma;   Stage III Bladder Cancer;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Laryngeal Verrucous Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Lip Basal Cell Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Merkel Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasal Type NK/T-Cell Lymphoma;   Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage III Oral Cavity Mucoepidermoid Carcinoma;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage III Oropharyngeal Undifferentiated Carcinoma;   Stage III Pancreatic Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IV Nasal Type NK/T-Cell Lymphoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Basal Cell Lip Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Oral Cavity Mucoepidermoid Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Undifferentiated Carcinoma;   Stage IVA Rectal Cancer;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Basal Cell Lip Carcinoma;   Stage IVB Colon Cancer;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Oral Cavity Mucoepidermoid Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Undifferentiated Carcinoma;   Stage IVB Rectal Cancer;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Basal Cell Lip Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Oral Cavity Mucoepidermoid Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Undifferentiated Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Tongue Carcinoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Romidepsin;   Other: Pharmacological Study
9 Not yet recruiting PARP Inhibitor BMN-673 in Treating Patients With BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Metastatic Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Cancer
Interventions: Drug: PARP Inhibitor BMN-673;   Other: Laboratory Biomarker Analysis
10 Recruiting Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Hormone-Resistant Breast Cancer;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Exemestane;   Drug: Entinostat;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
11 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2/Neu Positive;   Male Breast Carcinoma;   Metastatic Malignant Neoplasm to the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Lapatinib Ditosylate;   Radiation: Whole-Brain Radiotherapy;   Other: Laboratory Biomarker Analysis
12 Recruiting Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cyclophosphamide;   Other: Placebo;   Other: Laboratory Biomarker Analysis
13 Recruiting Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Conditions: HER2/Neu Positive;   Invasive Breast Carcinoma;   Male Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Lapatinib Ditosylate;   Biological: Trastuzumab;   Other: Laboratory Biomarker Analysis
14 Recruiting Sense of Hope Alleviates Fatigue in Breast Cancer Survivors
Condition: Carcinoma of Male Breast
Intervention:
15 Recruiting Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Melanoma;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Hepatocellular Carcinoma
Interventions: Drug: propranolol hydrochloride;   Other: Correlative Studies
16 Unknown  PD 0332991 in Treating Patients With Refractory Solid Tumors
Conditions: Adult Solid Tumor;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Benign Teratoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Familial Testicular Germ Cell Tumor;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Monodermal and Highly Specialized Teratoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Melanoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Rectal Cancer;   Stage III Extragonadal Non-seminomatous Germ Cell Tumor;   Stage III Extragonadal Seminoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Melanoma;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Rectal Cancer;   Testicular Immature Teratoma;   Testicular Mature Teratoma
Interventions: Drug: PD-0332991;   Other: pharmacological study
17 Recruiting Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: ganetespib;   Drug: paclitaxel;   Biological: trastuzumab;   Biological: pertuzumab
18 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
19 Recruiting Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Biological: trastuzumab;   Other: placebo;   Biological: polysaccharide-K;   Other: laboratory biomarker analysis
20 Recruiting Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mifepristone;   Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years